FINNENCE▪
00:00:00 UTCSYS ONLINE
FINNENCE ▪ THE WIRE FILE

THE WIRE · № 64227

News■ Unclear/unknown

Celaid Therapeutics Completes Second Close of Series B Financing Round

KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN2026-10-05 01:30 UTC
LAST UPDATE2026-10-05 01:30 UTC
STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

A private Japanese biotech Series B close is not publicly traded; it signals early-stage cell-therapy funding interest only.

Private biotech raise, no public market read-through
CATALYST TO WATCH

CLD-001 US trial progress

MAIN RISK

Clinical failure at private company

FULL DISPATCH

Shionogi & Co., Ltd. and Teikoku Ventures, Inc. Join the Round to Accelerate U.S. Clinical Trial Preparations for CLD-001 TOKYO, Oct. 4, 2026 /PRNewswire/ -- Celaid Therapeutics Inc. (Head Office: Bunkyo-ku, Tokyo, Japan; President and CEO: Nobuyuki Arakawa; "Celaid") today announced the...

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

AFFECTEDHealthcare
CONTEXTJapan

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED
№ 01prnewswireprnewswire.com · PRIMARY2026-10-05 01:30 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.